Page 3 of 4
Results 151 - 225 of 293
9916-cme-icon
Personalized Medicine for Improving Asthma Care: An Animated Video Series
9815-developments
New Developments in Pulmonary Diseases: Optimizing Patient Outcomes
9815-palliative slides
Palliative Medicine in Pulmonology
No image set
Patient Education, Adherence, Inhaler Technique, and Pulmonary Rehabilitation
No image set
Dyspnea and Disease are Progressing: What to Do?
No image set
Thoracic Radiology
No image set
A Closer Look at ILD, Sarcoidosis, and CTEPH
No image set
New Developments in Pulmonary Diseases: Optimizing Patient Outcomes
9916-0005-icon
Discussions with Patients to Optimize Asthma Control
9916-0004_treatment
Who Should be Targeted For Treatment With Biologic Therapy?
9916-0003_endotypes
Endotypes and Phenotypes in Asthma
9916-0002_moa3
Mechanisms of Action of Biologic Therapies for Severe Asthma
9916-0001_meds
Approved Medications for the Treatment of Severe Asthma
9907-0006_shared
Engage Your Patients in Shared Decision-Making
9907-0005_cardio
Is It IPF or Cardiovascular Disease?
9907-0004_ip
Interstitial Pneumonia with Autoimmune Features
9907-0003_pf-ild
How to Identify Progressive Fibrosing ILD
9907-0002_ctd
When Is It a Connective Tissue Disease?
9907-0001_guidelines
How to Use IPF Guidelines to Make a Diagnosis
9916-kalluri
Advanced Care Planning and Palliative Care Models for Patients with IPF
9916-kalluri
Dyspnea Assessment in Patients with IPF
9916-scholand1
Which Patients with IPF Should be on Antifibrotics?
9916-brown5
The Impact of Anticoagulation Use on IPF Patient Outcomes
9916-brown5
Patient-Centered Outcomes for Patients with IPF: Activity Monitoring
9916-solomon
Connective Tissue Disease-Related ILD is Now in the Limelight
9916-brown5
Biomarkers in IPF and Other ILDs
9840-glassberg2
Evaluation and Diagnosis of IPF
9840-glassberg1
Initial Treatment Decisions of IPF
curesma19-icon
The Changing Landscape of SMA–Updates from Anaheim, CA
9837-coolidge
What if President Calvin Coolidge Was Your Asthma Patient?
9840-0003
Optimizing Management of IPF
New_Concepts_in_the_Pathobiology_of_Asthma_264x150
New Concepts in the Pathobiology of Asthma
9916-king
What are the Most Exciting Things Happening in Pulmonary Disease?
No image set
When Is a Cough Not Just a Cough?
No image set
Diagnosing ILDs Such as IPF and More
No image set
Beyond the Basics: Complex ILD Cases
No image set
PowerPoint Slides: Achieving Better Control of Severe Asthma
9837-roosevelt
How Would You Manage President Theodore Roosevelt’s Asthma Today?
9916-scholand
New Tools to Improve the Diagnosis of IPF vs Other ILDs
9916-brown
New Research on Therapies for Patients with Pulmonary Fibrosis
9916-richeldi
The SENSCIS Trial: Exciting News for Scleroderma-Associated ILD
9916-cc-cme
2019 Summer Pulmonary Updates: The Experts Weigh In
No image set
U.S. Presidents with Severe Asthma: Endotypes and Precision Medicine
sma-journal-icon_263x0
Gene Therapy for SMA: An Emerging Treatment Option for a Devastating Disease
No image set
Reporting HRCT Findings for ILD from a Multidisciplinary Team
med-doc-aatd
A Closer Look at Alpha-1 Antitrypsin Deficiency: Peggy’s Story
med-doc-ph
How Pulmonary Arterial Hypertension Has Changed Iain’s Life
9834-0002
SMA: Data, Insights and Practice
9829-0001
From Bench to Bedside: Gene Therapy Approaches for Rare Diseases
9819-ntm case3
Management of Mycobacterium Abscessus Lung Disease
9819-ntm case2
Difficult to Treat Mycobacterium Avium Complex Lung Disease
9819-ntm case1
Management of Mycobacterium Avium Complex Lung Disease
9816-0001
The Latest from a Recent Pulmonary Conference in San Antonio
9816-0010
Updates in Inoperable CTEPH
9816-0009
The Importance of Early Integration of Palliative Care
9816-0006
Management of IPF Patients in 2018
9816-0005
Updates in the Diagnosis of ILD and the Role of Cryobiopsy
9816-00045
Overview of the Latest Clinical Trials in IPF
9816-0003
Evolution of Antifibrotic Therapy in IPF
9816-0002
Take Home Messages from the 2018 CHEST Annual Meeting
9816-0008
What We’re Learning from the IPF-PRO Registry
9816-0007
Comparing the 2017 Fleischner Society Guidelines and the 2018 ATS Guidelines
rePlace2
Emerging Treatments for NTM Lung Disease
rePlace2
Nontuberculous Mycobacteria Case 2: Alan
NTM_and_Treatment_Strategies_for_Patients_264x150
NTM and Treatment Strategies for Patients with Cavitary Disease
New_Findings_in_the_Treatment_of_MAC_264x150
New Findings in the Treatment of MAC Lung Disease
Why_You_Should_Pay_Attention_to_NTM_264x150
Why You Should Pay Attention to NTM Treatment Guidelines
Which_of_Your_Patients_Are_at_Risk_for_NTM_264x150
Which of Your Patients Are at Risk for NTM?
Practice_Improvement_through_ILD_Centers_264x150
Practice Improvement through ILD Centers and Community Partnerships
Improving_the_Care_for_IPF_Patients_264x150
Improving the Care for IPF Patients Using a Team-Based Approach
An_Early_Integrated_Palliative_Care_264x150
An Early Integrated Palliative Care Delivery Model for Patients with IPF
rePlace2
Treatment Challenges with MAC Lung Disease
rePlace2
Nontuberculous Mycobacteria: Summary
rePlace2
Treatment Challenges with MABC Lung Disease
rePlace2
Nontuberculous Mycobacteria Case 1: Maria
Page 3 of 4

Search